Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood

Clinical Chemistry

Volumn 58, Issue 3, 2012, Pages 599-609

  Klee, Eric W ^a   Bondar, Olga P ^a   Goodmanson, Marcia K ^a   Dyer, Roy B ^a   Erdogan, Sibel ^a   Bergstralh, Eric J ^a   Bergen III, H Robert ^a   Sebo, Thomas J ^a   Klee, George G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 3 FAMILY MEMBER B2; APOLIPOPROTEIN; APOLIPOPROTEIN C1; APOLIPOPROTEIN F; BIOLOGICAL MARKER; CADHERIN; CADHERIN 10 TYPE 2; CADHERIN 7 TYPE 2; CARRIER PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CHROMOSOME 1 OPEN READING FRAME 64; COLLAGEN; COLLAGEN TYPE 2 ALPHA1; COLLAGEN TYPE 9 ALPHA2; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; EPHRIN A4; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 116; LEUCINE RICH REPEAT NEURONAL 1; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; OXOGLUTARATE DEHYDROGENASE; PROTEIN ASPORIN; PROTEIN B3GNT6; PROTEIN LYSINE 6 OXIDASE; PROTEIN SERINE THREONINE KINASE; PROTEOGLYCAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE ADENOCARCINOMA; TANDEM MASS SPECTROMETRY;

ADENOCARCINOMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; RNA, MESSENGER; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84857857867     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.171637     Document Type: Article

References (30)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010.
2. Dickinson SI. Premalignant and malignant prostate lesions: pathologic review. Cancer Control 2010;17:214 -22.
3. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306. (Pubitemid 41646608)
4. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. Ca Cancer J Clin 2010;60:277-300.
5. Wasson JH, Bubolz TA, Yao GL, Barry MJ. Prostate biopsies in men with limited life expectancy. Eff Clin Pract 2002;5:137- 42.
6. Kube DM, Savci-Heijink CD, Lamblin AF, Kosari F, Vasmatzis G, Cheville JC, et al. Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer. BMC Mol Biol 2007;8:25.
7. Vasmatzis G, Klee EW, Kube DM, Therneau TM, Kosari F. Quantitating tissue specificity of human genes to facilitate biomarker discovery. Bioinformatics 2007;23:1348-55. (Pubitemid 47050516)
8. Kosari F, Munz JAM, Savci-Hejink CD, Spiro C, Klee EW, Kube DM, et al. Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res 2008;14:1734-43. (Pubitemid 351469458)
9. The Universal Protein Resource (UniProt) in 2010. Nucleic Acids Res 2010;38:D142-8.
10. Klee EW, Ellis LB. Evaluating eukaryotic secreted protein prediction. BMC Bioinformatics 2005;6:256.
11. Gerszten RE, Accurso F, Bernard GR, Caprioling RM, Klee EW, Klee GG, et al. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol 2008;295:L16-22.
12. Gasteiger E, Hoogland C, Gattiker A, Duvand S, Wilkins MR, Appel RD, Bairoch A. Protein identification and analysis tools on the ExPASy server. In: Walker JM, ed. The proteomics protocols handbook. Totowa (NJ): Humana Press; 2005. p 571-607.
13. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-10.
14. Julenius K, Molgaard A, Gupta R, Brunak S. Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology 2005;15:153-64. (Pubitemid 40227920)
15. Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 1999;294:1351-62. (Pubitemid 30008805)
16. Jameson BA, Wolf H. The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci 1988;4:181-6. (Pubitemid 18072035)
17. Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001;91:2196-204. (Pubitemid 32476386)
18. Anderson NL, Anderson GA, Haines LR, Hardie DB, Olafson RW, et al. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res 2004;3:235-44. (Pubitemid 38500990)
19. Anderson NL, Jackson A, Smith D, Hardie D, Borchers C, et al. SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics 2009;8:995-1005.
20. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943-53. (Pubitemid 38812467)
21. Bai VU, Kaseb A, Tejwani S, Divine GW, Barrack ER, Menon M, et al. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc Natl Acad Sci U S A 2007;104:2343-8. (Pubitemid 46391399)
22. Sardana G, Marshall J, Diamandis EP. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin Chem 2007;53:429-37. (Pubitemid 46447939)
23. Yang Y, Iyer LK, Adelstein SJ, Kassis AI. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer. PLos ONE 2008;3:1-8.
24. Romanuik TL, Ueda T, Le N, Haile S, Yong TM, Thomson T, et al. Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol 2009;175:2264-76.
25. Alonso V, Neves AF, Marangoni K, Faria PC, Freschi AP, Capaneli AC, et al. Gene expression profile in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Cancer Detect Prev 2009;32:336-7.
26. Iverson LH, Okholm M, Thorlacius-Ussing O. Preand postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease: a preliminary study. Thromb Haemost 1996;76:523-8. (Pubitemid 26372005)
27. Kohli M, Williams K, Yao JL, Dennis RA, Huang J, Reeder J, Ricke WA. Thrombin expression in prostate: a novel finding. Cancer Invest 2011;29:62-7.
28. Linge HM, Collin M, Giwercman A, Malm J, Bjartell A, Egesten A. The antibacterial chemokine MIG/CXCL9 is constitutively expressed in epithelial cells of the male urogenital tract and is present in seminal plasma. J Interferon Cytokine Res 2008;28:191-6. (Pubitemid 351380152)
29. Berghuis D, Santos SJ, Baelde HJ, Taminiau AH, Maarten Egeler R, Schilham MW, et al. Proinflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8 (+) T-lymphocyte infiltration and affect tumour progression. J Pathol 2011;223:347-57.
30. Hu W, Zhen X, Xiong B, Wang B, Zhang W, Zhou W. CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Sci 2008;99:1362-9. (Pubitemid 351761725)